Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
Clinical trial NCT03277261 · COMPLETED
Trial details
- NCT number
- NCT03277261
- Sponsor
- TG Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-19
- Primary completion
- 2020-07-23
- Enrollment
- 549
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.